Is Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Kiniksa Pharmaceuticals International, plc at current levels.
A one-drug company quietly becoming a two-drug franchise, with the second drug potentially bigger than the first.
Where KNSA is headed
ARCALYST is on track to clear $600M in 2026 revenue, growing 30%+, and Kiniksa is still only scratching the surface of the recurrent pericarditis patient pool. Diagnosis rates are climbing because rheumatologists and cardiologists finally have a label-indicated therapy to reach for, and the average treatment duration keeps extending as physicians learn the disease relapses hard when you pull patients off too early. That alone supports a credible path to $800M+ in peak ARCALYST sales without any heroic assumptions.
Read the full Compass Direction on KNSA
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $48.70).
See the full KNSA analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Kiniksa Pharmaceuticals International, plc at current levels. A one-drug company quietly becoming a two-drug franchise, with the second drug potentially bigger than the first.
What is KNSA's Compass Score?
Kiniksa Pharmaceuticals International, plc scores 90/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for KNSA?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the KNSA page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.